Ruth M. O’Regan, MD, discusses the development of oral selective estrogen receptor degraders in hormone receptor–positive breast cancer.
Ruth O'Regan, MD, University of Rochester Medical Center
Advertisement
Articles by Ruth O'Regan, MD, University of Rochester Medical Center
Advertisement
Latest Updated Articles
Dr. O’Regan on the Development of Oral SERDs in Breast CancerPublished: August 9th 2022 | Updated:
Prognostic Tools for Early-Stage HER2+ Breast CancerPublished: January 25th 2021 | Updated:
Current Treatment Landscape for HER2+ Breast CancerPublished: January 25th 2021 | Updated:
Updated Data for Metastatic HER2+ Breast CancerPublished: January 25th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5